Stand Up To Cancer

October 26, 2017

Study to test combination therapy for breast cancer

Vanderbilt-Ingram Cancer Center (VICC) has received $2.3 million to fund a clinical research trial testing a combination of three immunotherapy compounds for patients with a specific type of advanced breast cancer.

By VUMC News and Communications

April 3, 2017

Vanderbilt investigator lands Stand Up To Cancer grant for “smart” nanoparticles cancer research

John Wilson, Ph.D., assistant professor of Chemical and Biomolecular Engineering and of Biomedical Engineering at Vanderbilt University, has received an Innovative Research Grant from Stand Up To Cancer (SU2C). Wilson is among 10 early-career scientists to receive the grant awards focused on immuno-oncology.

December 19, 2013

VU study identifies new gene fusions in melanoma

Cancer researchers, led by investigators at Vanderbilt-Ingram Cancer Center, have identified two novel gene fusions in melanoma that may be responsive to existing cancer therapies. Melanoma is the most deadly form of skin cancer.

By VUMC News and Communications

September 12, 2013

VU study identifies DNA changes in drug-resistant cancer cells

Vanderbilt investigators have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines.

By Leigh MacMillan

September 21, 2012

HER2 may impact lung cancer therapy

A protein associated with aggressive breast cancers may also influence resistance of lung cancer to targeted therapies.

By VUMC News and Communications

June 11, 2012

Vanderbilt identifies genes linked to breast cancer chemo resistance

A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer.

By VUMC News and Communications